Cardiac AI: Investing in Continuous Monitoring’s Next Billion

The digital health market is finally consolidating after years of being a fragmented mess of niche point solutions. This convergence is happening because companies need to land bigger enterprise contracts and show they can do more than just one thing, a trend that’s especially obvious as platforms expand into continuous cardiovascular monitoring. For investors trying to spot the winners, it means looking past the funding velocity and digging into the actual clinical and technical depth of a company’s expansion plans.

The Strategic Pivot: From Niche to Complete Care

In digital health, sustained revenue growth is everything, and achieving it now means offering integrated solutions that cover several chronic conditions. Companies that got their foot in the door with a strong wedge product are now using those relationships with employers and health plans to tackle the interconnected mess of chronic diseases, with cardiovascular health usually being a key part of the puzzle. This whole evolution is a direct answer to big payers and self-insured employers who are tired of managing a dozen different single-condition apps and just want one simplified, evidence-based platform. Take Hinge Health, which completely carved out the musculoskeletal (MSK) market for itself. While Sword Health is still a tough competitor in MSK, Hinge Health’s path shows it’s aiming for something much bigger. Their massive funding rounds, like a Series D in January 2021 that put them at a $3 billion valuation and a Series E just months later in October 2021 at $6.2 billion, show that investors believe they can grow beyond their initial market. Hinge Health completed its IPO in May 2025, listing on the NYSE under the ticker HNGE. While Hinge hasn’t officially announced a dedicated continuous cardiovascular monitoring program, its entire strategy is about expanding into broader care, making cardiometabolic health, with its clear ties to MSK conditions, the obvious next move for product development and landing those bigger enterprise deals. This kind of platform consolidation is a strong indicator of long-term growth because it actually meets the real-world needs of the people they cover.

Omada Health: A Blueprint for Integrated Cardiometabolic Programs

Omada Health is a perfect blueprint for how a digital health company can successfully build out complete cardiometabolic programs that touch on continuous cardiovascular monitoring. They started out known for their diabetes prevention program, but Omada has methodically bolted on programs for hypertension, pre-diabetes, and obesity management. This isn’t just adding more features. It’s an integrated system that gets that these conditions are all comorbid. For investors, Omada’s cardiovascular expansion numbers are very persuasive. Their programs typically use devices for remote monitoring of blood pressure and glucose which, even if they aren’t “continuous” like a wearable ECG, generate the critical real-world evidence (RWE) needed to manage a condition effectively. All that data creates a valuable moat, letting Omada sharpen its algorithms and prove real clinical results to health plans. The fact that the company is landing enterprise contracts with huge employers and health plans covering millions of people proves its integrated model works and can scale. We can’t see specific SEC filings on their cardiovascular program revenue, but their public growth reports and repeated funding rounds, including a $192 million Series E in February 2022, suggest the market is buying what they’re selling. Omada Health completed its IPO in June 2025, listing on NASDAQ under the ticker OMDA. The strategy for companies like Omada is simple: offer one platform for multiple chronic conditions to cut down the administrative headache for payers and get patients to stick with it through a single, familiar app. It’s a model that’s incredibly appealing to Fortune 500 companies trying to get their employee health benefits and rising healthcare costs under control.

The Role of Mental Health in Cardiovascular Care Expansion

The link between mental and cardiovascular health is so well-established now that mental health integration is becoming a must-have for any complete digital health platform. Spring Health, a leader in mental health benefits for employers, is a great case study here. They aren’t directly in the continuous cardiovascular monitoring business, but their success in winning enterprise deals and their fast growth shows the power of tackling a health area that’s both underserved and deeply connected to physical health. For investors, what’s happening with Spring Health points to a bigger truth: solutions that treat the whole person are the ones gaining real traction. As digital health companies get more mature, the ones that can smoothly weave mental health support into their physical health programs are going to have a serious competitive edge. While Spring Health’s focus today is on mental well-being, the platform itself and its proven ability to keep users engaged could easily be pointed at broader health applications, including ones that address cardiovascular risk factors tied to stress. Could this lead to strategic partnerships or product expansions that touch the cardiovascular monitoring space? It seems likely.

Platform Consolidation vs. Point Solutions: An Investor’s Takeaway

The trend is clear: the digital health market is shifting from a zillion single-point solutions to complete, multi-specialty platforms. This is being driven by large enterprise clients and health plans that want to deal with fewer vendors who offer broader, integrated services. For investors, this means you have to evaluate companies on their strategic roadmap for expansion and their ability to actually integrate different health services, not just on what they sell today. Companies with a clear plan to address multiple chronic conditions, cardiovascular health included, are the ones in the best position for long-term growth and market leadership. The regulatory environment, which is getting tougher on digital health, also gives an edge to established players who have strong clinical evidence and a track record of user engagement and good outcomes. A company that has its quality management system (QMS) in order and has gone through the trouble of getting ISO 13485 certification requirements, for example, is signaling it’s built for the long haul and ready for regulatory scrutiny, which makes it a safer bet. The “fastest growing AI health companies” are the ones that see these market dynamics coming and adapt. They’re building more than just tech. They’re building platforms that solve the messy, interconnected health problems of large populations which is how they secure deeper enterprise contracts and grow the number of lives they cover.

Methodology Note: Using Aggregate Venture Data

Our analysis is driven by data. We use aggregate data to find and profile companies that are succeeding, which means digging through venture funding reports, public company statements, and industry analysis to figure out their strategy and market traction. Of course, the specific financials for private companies are kept under wraps, but the speed and size of funding rounds, combined with announced enterprise contract wins and new clinical expansions, are strong proxies for revenue growth and market position. We focus on these validated growth signals, because in a market that moves this fast, investment capital tends to chase companies that have already proven they can handle large-scale deployments and deliver real clinical value.